Dabrafenib and trametinib either in combination or as monotherapy in pediatric patients harboring BRAF alterations in gliomas or other rare tumors: Findings from a managed access program

Background: To enable global access to therapies in countries where suitable formulations and/or indications are not yet approved, managed access programs (MAPs) are established. Herein, we report patient data from a MAP for pediatric patients with BRAF-altered gliomas or other rare tumors, seeking...

Full description

Bibliographic Details

Published in:	EJC Paediatric Oncology
Main Authors:	Mark Russo, AnaRita Ferreira, Michael Roughton, Sviatlana Rizk, Naveen Chhabra, Manar Aoun
Format:	Article
Language:	English
Published:	Elsevier 2025-06-01
Subjects:	BRAF alterations Managed access program Pediatric gliomas Targeted therapy Langerhans cell histiocytosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772610X25000248